NASDAQ:GLMD

Galmed Pharmaceuticals Stock News

Healthcare > Biotechnology

Buy GLMD

*Your capital is at risk

$0.621

+0.0220 (+3.67%)

At Close: Jul 31, 2026

Galmed Announces Breakthrough Development of Dispersible Film Delivery (ODF), Brain Penetrating formulation of its SCD1 inhibitor Aramchol for Parkinson's Disease, Targeting $6 Billion Market

07:00am, Tuesday, 28'th Jul 2026

Aramchol meglumine is the only SCD1 inhibitor with an established clinical safety profile and confirmed blood-brain barrier (BBB) penetration. In order to improve patient convenience and long-term tre

Galmed Pharmaceuticals (GLMD) Projected to Announce Quarterly Earnings on Thursday

02:27am, Thursday, 23'rd Jul 2026

Galmed Pharmaceuticals (NASDAQ: GLMD - Get Free Report) is expected to issue its results before the market opens on Thursday, July 30th. Analysts expect the company to post earnings of ($0.39) per sha

Galmed Announces the Breakthrough Development of Novel LNP Cardiac Targeted Formulation of its SCD1 inhibitor, Aramchol

07:30am, Thursday, 16'th Jul 2026

Galmed has developed, in collaboration with Barcode Nanotech, a unique proprietary lipid nanoparticles (LPNs) novel formulation of Aramchol that penetrates the heart tissue and redirects Aramchol's bi

Galmed Pharmaceuticals Ltd. Announces Restructured Acquisition Terms for Colospan Ltd.

07:00am, Monday, 22'nd Jun 2026

Colospan Ltd. ("Colospan") provides Galmed Pharmaceuticals Ltd.

Galmed Pharmaceuticals to Acquire Colospan to Create a GI-Focused Platform Targeting a $6 Billion Market

08:10am, Monday, 08'th Jun 2026

Transaction will add FDA Breakthrough Device-Designated technology with active U.S. pivotal IDE trial, positioning Galmed to address one of colorectal surgery's most serious unmet needs. Colospan's CG

Tissue Dynamics and Galmed Unveil Unknown Metabolic Pathway for Cardiac Fibrosis and Heart Failure which Supports the Development of Aramchol for Cardiac Fibrosis

07:30am, Tuesday, 02'nd Jun 2026

- Tissue Dynamics identified a previously unrecognized metabolic mechanism driving cardiac fibrosis using a human cardiac organoid model, revealing disease biology that is not accessible through conve

Galmed Announces Results from First-in-Man Pharmacokinetics Study of Oral Formulation of Aramchol Meglumine (AM); 400mg AM Increases Bioavailability by ~500% in Comparison to Aramchol Free Acid (AA) 300mg

07:30am, Thursday, 14'th May 2026

Results from Study AM-001 mark a pivotal advance through the transition to a once daily lower 400mg dose of AM enabling: Production of GMP clinical batch for Galmed's upcoming clinical trials Solidifi

Tissue Dynamics and Galmed Pharmaceuticals to Develop Human-Centered Chronic Cardiac Fibrosis Platform to Advance Aramchol-Based Therapeutics

07:30am, Wednesday, 06'th May 2026

Novel vascularized, sensor-embedded cardiac organoid model will focus on chronic post-MI remodeling and HFpEF, linking lipid metabolism, SCD1 activity, fibrosis, and impaired tissue repair REHOVOT, Is

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Short Interest Update

02:38am, Saturday, 25'th Apr 2026

Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD - Get Free Report) was the target of a large growth in short interest during the month of April. As of April 15th, there was short interest totaling 502,390 s

Galmed Announces a Collaboration Agreement with Tel Aviv University to Evaluate its SCD1 inhibitor, Aramchol, as a Targeted Therapy for Metastatic Brain Cancers

07:30am, Tuesday, 14'th Apr 2026

Recently, Galmed announced breakthrough medicinal chemistry work converting Aramchol into a brain-penetrant SCD1 inhibitor, potentially positioning Aramchol as a first-in-class therapy for synucleino

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by